174 related articles for article (PubMed ID: 35859262)
1. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer.
Xu JL
Dig Dis Sci; 2023 Mar; 68(3):831-840. PubMed ID: 35859262
[TBL] [Abstract][Full Text] [Related]
2. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
[TBL] [Abstract][Full Text] [Related]
3. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
4. IL2RA is a prognostic indicator and correlated with immune characteristics of pancreatic ductal adenocarcinoma.
Fan L; Wang X; Chang Q; Wang Y; Yang W; Liu L
Medicine (Baltimore); 2022 Oct; 101(42):e30966. PubMed ID: 36281157
[TBL] [Abstract][Full Text] [Related]
5. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.
Kocher F; Puccini A; Untergasser G; Martowicz A; Zimmer K; Pircher A; Baca Y; Xiu J; Haybaeck J; Tymoszuk P; Goldberg RM; Petrillo A; Shields AF; Salem ME; Marshall JL; Hall M; Korn WM; Nabhan C; Battaglin F; Lenz HJ; Lou E; Choo SP; Toh CK; Gasteiger S; Pichler R; Wolf D; Seeber A
Clin Cancer Res; 2022 Nov; 28(22):4957-4967. PubMed ID: 36112544
[TBL] [Abstract][Full Text] [Related]
6. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
7. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma.
Herremans KM; Szymkiewicz DD; Riner AN; Bohan RP; Tushoski GW; Davidson AM; Lou X; Leong MC; Dean BD; Gerber M; Underwood PW; Han S; Hughes SJ
Neoplasia; 2022 Jun; 28():100789. PubMed ID: 35395492
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
9. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer.
Hou Z; Pan Y; Fei Q; Lin Y; Zhou Y; Liu Y; Guan H; Yu X; Lin X; Lu F; Huang H
J Cancer Res Clin Oncol; 2021 Feb; 147(2):517-531. PubMed ID: 33237432
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
12. Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma.
Cattaneo G; Ventin M; Arya S; Kontos F; Michelakos T; Sekigami Y; Cai L; Villani V; Sabbatino F; Chen F; Sadagopan A; Deshpande V; Moore PA; Ting DT; Bardeesy N; Wang X; Ferrone S; Ferrone CR
Cancer Lett; 2024 Apr; 587():216713. PubMed ID: 38364961
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
14.
Deng J; Zhang J; Ye Y; Liu K; Zeng L; Huang J; Pan L; Li M; Bai R; Zhuang L; Huang X; Wu G; Wei L; Zheng Y; Su J; Zhang S; Chen R; Lin D; Zheng J
Cancer Res; 2021 Oct; 81(20):5268-5283. PubMed ID: 34362795
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G
J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932
[TBL] [Abstract][Full Text] [Related]
16. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
17. Up-Regulated MISP Is Associated With Poor Prognosis and Immune Infiltration in Pancreatic Ductal Adenocarcinoma.
Huang X; Zhao L; Jin Y; Wang Z; Li T; Xu H; Wang Q; Wang L
Front Oncol; 2022; 12():827051. PubMed ID: 35433491
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma.
Jiang Y; Han L; Yang J; Yang M; Zhang J; Xue M; Zhu Y; Xiong C; Shi M; Zhao S; Shen B; Xu Z; Jiang L; Chen H
Cancer Immunol Immunother; 2023 Aug; 72(8):2701-2716. PubMed ID: 37097516
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]